COEP (Coeptis Therapeutics Holdings) 3-Year RORE % : -56.49% (As of Dec. 2025)


COEP Coeptis Therapeutics Holdings Inc COEP
12 GF Score
Price $16.40
View Full Analysis

What is Coeptis Therapeutics Holdings 3-Year RORE %?

Coeptis Therapeutics Holdings COEP +1.52% 12 3-Year RORE % is -56.49 as of Dec. 2025. GuruFocus rates COEP with a GF Score™ of 12/100.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Coeptis Therapeutics Holdings's 3-Year RORE % for the quarter that ended in Dec. 2025 was -56.49%.

The industry rank for Coeptis Therapeutics Holdings's 3-Year RORE % or its related term are showing as below:

COEP's 3-Year RORE % is not ranked
in the Biotechnology industry.
Industry Median: -11.44 vs COEP: -56.49

Coeptis Therapeutics Holdings  (NAS:COEP) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Coeptis Therapeutics Holdings 3-Year RORE % Related Terms


Coeptis Therapeutics Holdings 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Coeptis Therapeutics Holdings's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coeptis Therapeutics Holdings 3-Year RORE % Chart

Coeptis Therapeutics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 5.93 -52.77 -56.49

Coeptis Therapeutics Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.77 -50.50 -45.78 -52.18 -56.49

COEP vs ANIX, COYA, PMN: 3-Year RORE % Comparison

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coeptis Therapeutics Holdings 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's 3-Year RORE % falls into.


COEP
12GF Score
Coeptis Therapeutics Holdings Inc COEP
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coeptis Therapeutics Holdings 3-Year RORE % Calculation

Coeptis Therapeutics Holdings's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -2.764--17.16 )/( -25.484-0 )
=14.396/-25.484
=-56.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -56.49 mean?
Coeptis Therapeutics Holdings (COEP) has a 3-Year RORE % of -56.49 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Coeptis Therapeutics Holdings and its competitors.
Is Coeptis Therapeutics Holdings' 3-Year RORE % too high?
Coeptis Therapeutics Holdings' current 3-Year RORE % is -56.49. Overall, Coeptis Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Coeptis Therapeutics Holdings' 3-Year RORE % compare to ANIX and COYA?
Coeptis Therapeutics Holdings' 3-Year RORE % of -56.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Coeptis Therapeutics Holdings and its competitors. Coeptis Therapeutics Holdings's current 3-Year RORE % is -56.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coeptis Therapeutics Holdings stock overvalued right now?
Coeptis Therapeutics Holdings (COEP) has a current 3-Year RORE % of -56.49. The current 3-Year RORE % is -56.49. Coeptis Therapeutics Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Coeptis Therapeutics Holdings (COEP), the current 3-Year RORE % is -56.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coeptis Therapeutics Holdings Business Description

Address 105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
12GF Score

Get the complete analysis for COEP

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.40
Price